Cargando…

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials

SIMPLE SUMMARY: We investigated for the first time the safety profile of COVID-19 vaccines in patients receiving new antineoplastic agents in early-stage clinical trials, including new immuno-regulatory anti-cancer investigational compounds and drug combinations. We found that about three-quarters o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Trillo Aliaga, Pamela, Trapani, Dario, Sandoval, José Luis, Crimini, Edoardo, Antonarelli, Gabriele, Vivanet, Grazia, Morganti, Stefania, Corti, Chiara, Tarantino, Paolo, Friedlaender, Alex, Belli, Carmen, Minchella, Ida, Locatelli, Marzia, Esposito, Angela, Criscitiello, Carmen, Curigliano, Giuseppe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616209/ https://www.ncbi.nlm.nih.gov/pubmed/34830983 http://dx.doi.org/10.3390/cancers13225829

Ejemplares similares

1583P COVID-19 related risk in patients enrolled in early-phase clinical trials
por: D'Amico, P., et al.
Publicado: (2021)

Predicting Response to Antibody Drug Conjugates: A Focus on Antigens’ Targetability
por: Ascione, Liliana, et al.
Publicado: (2023)

Targeting Cellular Components of the Tumor Microenvironment in Solid Malignancies
por: Belli, Carmen, et al.
Publicado: (2022)

Best management of locally advanced inoperable breast cancer
por: Curigliano, Giuseppe, et al.
Publicado: (2013)

Immune approaches to the treatment of breast cancer, around the corner?
por: Criscitiello, Carmen, et al.
Publicado: (2014)

Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls
por: Morganti, Stefania, et al.
Publicado: (2022)

PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative
por: Ascione, Liliana, et al.
Publicado: (2022)

Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives
por: Criscitiello, Carmen, et al.
Publicado: (2014)

HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer
por: Venetis, Konstantinos, et al.
Publicado: (2022)

Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards
por: Crimini, Edoardo, et al.
Publicado: (2022)

Antibody–drug conjugates in solid tumors: a look into novel targets
por: Criscitiello, Carmen, et al.
Publicado: (2021)

Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
por: Marra, Antonio, et al.
Publicado: (2020)

Tumour dormancy and clinical implications in breast cancer
por: Gelao, L, et al.
Publicado: (2013)

Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
por: Antonarelli, G., et al.
Publicado: (2023)

SARS-CoV-2 vaccines for cancer patients: a call to action
por: Corti, Chiara, et al.
Publicado: (2021)

Research and Clinical Landscape of Bispecific Antibodies for the Treatment of Solid Malignancies
por: Antonarelli, Gabriele, et al.
Publicado: (2021)

Targeting Post-Translational Modifications to Improve Combinatorial Therapies in Breast Cancer: The Role of Fucosylation
por: Antonarelli, Gabriele, et al.
Publicado: (2023)

Highlights from the 14(th) St Gallen International Breast Cancer Conference 2015 in Vienna: Dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer
por: Esposito, Angela, et al.
Publicado: (2015)

Tumor Infiltrating Lymphocytes across Breast Cancer Subtypes: Current Issues for Biomarker Assessment
por: Valenza, Carmine, et al.
Publicado: (2023)

Sustained Improvement in the Management of Patients with Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocation: Where Are We Running?
por: Spitaleri, Gianluca, et al.
Publicado: (2023)

Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–related disease pandemic
por: Tarantino, Paolo, et al.
Publicado: (2020)

Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an “Innocent Bystander”
por: Gelao, Lucia, et al.
Publicado: (2014)

Opportunities and challenges of implementing Pharmacogenomics in cancer drug development
por: Tarantino, Paolo, et al.
Publicado: (2019)

Therapeutic cancer vaccines revamping: technology advancements and pitfalls
por: Antonarelli, G., et al.
Publicado: (2021)

Expression of tumor-associated antigens in breast cancer subtypes
por: Curigliano, Giuseppe, et al.
Publicado: (2019)

Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets
por: Lammers, Philip, et al.
Publicado: (2014)

Profile of buparlisib and its potential in the treatment of breast cancer: evidence to date
por: Criscitiello, Carmen, et al.
Publicado: (2018)

Toward precision medicine in inflammatory breast cancer
por: Viale, Giulia, et al.
Publicado: (2019)

Targeting HER2 in breast cancer: new drugs and paradigms on the horizon
por: Tarantino, Paolo, et al.
Publicado: (2021)

Breast Cancer Genetics: Diagnostics and Treatment
por: Criscitiello, Carmen, et al.
Publicado: (2022)

How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed?
por: Morganti, S., et al.
Publicado: (2022)

Master protocols in immuno-oncology: do novel drugs deserve novel designs?
por: Mazzarella, Luca, et al.
Publicado: (2020)

COVID-19 vaccines in patients with cancer
por: Trapani, Dario, et al.
Publicado: (2021)

Accelerating progress in early triple-negative breast cancer: A viewpoint on antibody-drug conjugates, back from St Gallen breast cancer conference 2021()
por: Trapani, Dario, et al.
Publicado: (2021)

Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?
por: Curigliano, Giuseppe, et al.
Publicado: (2013)

Impact of autoimmune diseases on outcome of patients with early breast cancer
por: Criscitiello, Carmen, et al.
Publicado: (2016)

Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution
por: Giugliano, Federica, et al.
Publicado: (2023)

Seroconversion rate after vaccination against COVID-19 in patients with cancer—a systematic review
por: Corti, C., et al.
Publicado: (2022)

Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy
por: Viale, Giulia, et al.
Publicado: (2017)

The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region
por: Trapani, Dario, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_9q5f01t238voamj2rg0qpmbogv